Compare Divis Laboratories with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs VENUS REMEDIES - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES VENUS REMEDIES DIVIS LABORATORIES/
VENUS REMEDIES
 
P/E (TTM) x 58.8 -7.8 - View Chart
P/BV x 13.5 0.5 2,608.6% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 DIVIS LABORATORIES   VENUS REMEDIES
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
VENUS REMEDIES
Mar-18
DIVIS LABORATORIES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,639126 1,302.1%   
Low Rs1,11561 1,824.9%   
Sales per share (Unadj.) Rs186.3301.8 61.7%  
Earnings per share (Unadj.) Rs51.0-24.9 -204.9%  
Cash flow per share (Unadj.) Rs57.32.5 2,252.6%  
Dividends per share (Unadj.) Rs16.000-  
Dividend yield (eoy) %1.20-  
Book value per share (Unadj.) Rs261.8293.3 89.3%  
Shares outstanding (eoy) m265.4712.34 2,151.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.40.3 2,385.7%   
Avg P/E ratio x27.0-3.8 -718.9%  
P/CF ratio (eoy) x24.036.7 65.4%  
Price / Book Value ratio x5.30.3 1,650.2%  
Dividend payout %31.40-   
Avg Mkt Cap Rs m365,5921,154 31,686.2%   
No. of employees `00011.80.9 1,280.8%   
Total wages/salary Rs m5,423393 1,379.5%   
Avg. sales/employee Rs Th4,175.14,026.1 103.7%   
Avg. wages/employee Rs Th457.7425.0 107.7%   
Avg. net profit/employee Rs Th1,141.8-331.8 -344.2%   
INCOME DATA
Net Sales Rs m49,4633,724 1,328.2%  
Other income Rs m1,55623 6,916.9%   
Total revenues Rs m51,0193,747 1,361.7%   
Gross profit Rs m18,718395 4,741.2%  
Depreciation Rs m1,689338 499.3%   
Interest Rs m35354 9.9%   
Profit before tax Rs m18,551-275 -6,738.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,02332 15,896.5%   
Profit after tax Rs m13,527-307 -4,407.8%  
Gross profit margin %37.810.6 357.0%  
Effective tax rate %27.1-11.5 -235.9%   
Net profit margin %27.3-8.2 -331.9%  
BALANCE SHEET DATA
Current assets Rs m46,5012,638 1,762.9%   
Current liabilities Rs m8,4682,305 367.4%   
Net working cap to sales %76.98.9 859.8%  
Current ratio x5.51.1 479.8%  
Inventory Days Days131135 96.6%  
Debtors Days Days8646 185.3%  
Net fixed assets Rs m25,7974,871 529.6%   
Share capital Rs m531123 430.2%   
"Free" reserves Rs m68,9623,496 1,972.8%   
Net worth Rs m69,4933,619 1,920.2%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m80,3837,509 1,070.6%  
Interest coverage x531.00.2 238,152.4%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.5 124.1%   
Return on assets %16.90.6 2,672.7%  
Return on equity %19.5-8.5 -229.5%  
Return on capital %26.71.6 1,690.5%  
Exports to sales %00-   
Imports to sales %24.613.9 177.6%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187517 2,359.3%   
Fx inflow Rs m41,2380-   
Fx outflow Rs m12,405517 2,401.8%   
Net fx Rs m28,833-517 -5,582.3%   
CASH FLOW
From Operations Rs m9,543514 1,855.2%  
From Investments Rs m-6,854-123 5,567.8%  
From Financial Activity Rs m-2,459-387 635.3%  
Net Cashflow Rs m2304 5,466.7%  

Share Holding

Indian Promoters % 52.0 32.9 158.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 0.2 6,555.6%  
FIIs % 19.0 0.6 3,275.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 66.4 25.9%  
Shareholders   31,796 20,121 158.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  FULFORD INDIA  ORCHID PHARMA  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 22, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS